6/11/2015
1
OSTEOPOROSIS UPDATE2015
Heather Hofflich, DO, FACE
Associate Clinical Professor of Medicine
University of California, San Diego
Introduction
Osteoporosis
FRAX
Diagnosis/Secondary Causes
Therapies
Controversies
NOF Guidelines
Osteoporosis: The Definition
• Impaired bone strength
– Low BMD
– poor bone quality
• Increased fracture risk
due to bone loss
6/11/2015
2
Osteoporosis
1.Micro-architecture 1. Size and
2. Turnover/stress geometry
3. Damage 2. Mineralization
4. Matrix quality
Bone Strength Bone Qualities Bone Density= +
Hip Fracture
6/11/2015
4
DEXA
• DEXA measure only two areas:
BONE MINERAL CONTENT (G)
AREA (CM2)
WHO Bone Density Criteria
Diagnostic Criteria* Classification
•T score = BMD compared to a “young normal” adult of the same sex• Z score= BMD compared to a “young normal” adult of the same AGEand sex
T is above or equal to -1.0 Normal bone density
T is between -1.0 and -2.5 Osteopenia
T is -2.5 or lower Osteoporosis
T is -2.5 or lower Severe established
+fragility fracture osteoporosis
NOF Indications for BMD testing
• Women age 65 years and older
• Men age 70 years and older
• Age 50-69 with risk factor
• Fracture after age 50
• Women in menopausal transition if a specificrisk factor (low body weight, prior low-traumafracture or high risk medication)
6/11/2015
5
How Often Should I Have a DXA?
• Important to have DXA on same machine(brand) preferable at same location as priorstudy
• Every 2 years per Medicare
• Recent studies state if osteopenia--?repeat in5 years or longer
Secondary Causes ofOsteoporosis
Secondary Causes of Osteoporosis
Adapted from AACE Guidelines onosteoporosis, 2001
6/11/2015
6
Medications that cause osteoporosis
• Glucocorticoids (≥ 5 mg/d
of prednisone for ≥ 3 months)
• Immunosuppresants(cyclosporines, tacrolimus)
• Heparin/Coumadin
• Anticonvulsants(gabapentin)
• Opioids
• PPI’s
• Lithium
• Aromatase Inhibitors
• Androgen DeprivationTherapy
• Depo Provera
• Excess thyroidmedication
• SSRI’s
• TZD’s
PPI’s and hip fracture
• Study in 2006 showed possible association btwn hipfractures and chronic PPI use
– Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapyand risk of hip fracture. JAMA : the journal of the American Medical Association.2006;296(24):2947-53. Epub 2006/12/28.
• PPI use and increased risk for hip fracture in tobaccousers– Khalili H, Huang ES, Jacobson BC, Camargo CA, Jr., Feskanich D, Chan AT. Use of
proton pump inhibitors and risk of hip fracture in relation to dietary and lifestylefactors: a prospective cohort study. BMJ. 2012;344:e372. Epub 2012/02/02.
•
Lab Tests for Secondary Causes ofBone Loss
• CBC
• CMP
• 24 hour urinecalcium/creatinine
• TSH
• 25-OH vitamin D
• Testosterone (Males
• SPEP/UPEP
• TTGIGA (celiac)
• Phosphorus
• Magnesium
• PTH
6/11/2015
10
FRAX Summary
• If t score is between -1.0 and -2.5 treatment isrecommended if:
The 10 year probability of a hip fracture is≥ 3%
The 10-year probability of a majorosteoporosis-related fracture ≥ 20
Prevention ofOsteoporosis
6/11/2015
11
31
Non pharmacological approachesto the prevention of
osteoporosis
• Adequate intake of dietary calcium
• Regular physical activity
• Minimize alcohol intake—1-2 small glasses/daily
• Encourage smoking cessation
• Minimize risk of fall
Your mother always toldyou to drink your milk…
She was right!
Current Calcium Recommendations
• 1200 mg daily for women older than 50
• 1000 mg daily for men older than 50
• 1200 mg daily for men older than 70
• Try and obtain from food sources, thensupplement
6/11/2015
12
Calcium and MI association?
• 2010 metanalysis showed possible assoc.btwn MI and >1500 mg of calcium daily– Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et
al. Effect of calcium supplements on risk of myocardial infarction andcardiovascular events: meta-analysis. BMJ 2010;341:c3691
• However, recent study showed no assoc.btwn. calcium and inc. risk of MI– Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ,
Anderson GL, et al. Health risks and benefits from calcium and vitamin Dsupplementation: Women's Health Initiative clinical trial and cohort study.Osteoporosis international : a journal established as result of cooperationbetween the European Foundation for Osteoporosis and the NationalOsteoporosis Foundation of the USA. 2012. Epub 2012/12/05.
Calcium Calculator
Product Servings/Day Calcium (mg) Total
Milk (8 oz.) X 300 =
Yogurt (6 oz.) X 300 =
Cheese (1 oz. or 1cubic inch)
X 200 =
FortifiedFoods/Juices
X 80-1,000 =
Estimated total from other foods = 250
Total daily calcium intake, in mg =
Which Type of Calcium?
• Calcium Carbonate---needs to be taken withfood for best absorption
• Calcium Citrate—does not need to be takenwith food
• Calcium Phosphate
• Calcium Gluconate
• Calcium Lactate
6/11/2015
13
Calcium Supplements
Vitamin D
• Vitamin D is added to milk and OJ andis in liver and fatty fish.
• You can get vitamin D from the sun.But, you need sunscreen to protectyour skin which also blocks vitamin D.
• To get enough vitamin D, many peopleneed to take a supplement.
Vitamin D
• 800-1000 IU daily
• Max. dose recommended : 4000 IU daily
• Recent studies show no association withcardiovascular disease or reduction in breastcancer
6/11/2015
14
EXERCISE
Weight-bearing Exercises
• Which exercise is for you?
– Low impact: walking, elliptical, low impactaerobics, stair-stepper, tai chi
– High impact: jogging or running, aerobicdancing, hiking, jumping rope, stair climbing
Weight-bearing Exercises
• Which exercise is for you?– Try to do the exercises with greatest impact
that do not cause problems
• Try to do 30 minutes of weight-bearingexercise, at a moderate pace, most daysof the week
6/11/2015
15
Muscle-strengthening Exercises
• Muscle-strengthening exercises makeyou move your body, a weight or someother resistance against gravity
• Some options include:– Lifting weights (machines or free weights)
– Calisthenics (partial or full push ups, wallslide/wall sits, prone trunk lifts)
– Using exercise bands or tubes
Fall Prevention
• Have your eyes checked
• Have your medications checked
• Stay active and do weight bearing exercise
• If needed use walker, cane or other source tohelp prevent falls
• Ask you doctor about physical therapy
6/11/2015
16
What about Caffeine?
• Coffee--calcium intake with coffee
• Tea—?evidence
• Soda—Cola—Tufts study showed phosphoricacid did cause significant bone loss
Alcohol and Tobacco
• Minimize ETOH use to <2 glasses daily
• Smoking cessation is key to healthy bones
Therapies forOsteoporosis
6/11/2015
17
FDA approved therapies forOsteoporosis
• Bisphosphonates–Alendronate–Risedronate– Ibandronate–Zolendronic Acid
• Raloxifene• Denosumab• Teripartide- formation
• Life stylemodifications– Calcium and vitamin D– Weight bearing exercises– Fall prevention
50
Osteoclast
Inhibition of resorption
Osteoblast
Stimulation of formation
Treatment objectives
Benefits of Osteoporosis Therapy
• Reduction in fracture risk
• Reduction in pain and disability
• Preservation of independence
• Reduction in height loss
• Positive effect on mortality (?)
• Positive effect on BMD
6/11/2015
18
Bisphosphonates
• Work by inhibiting osteoclast function
• Oral and IV forms
• Side effects:
– Renal impairment
– Rash
– Esophagitis
– Osteonecrosis of the Jaw
Atypical Femur Fracture
• Located at diaphyseal area
• Lateral cortical thickening
• Transverse Fracture with short obliqueextension medially (beaking)
• Often Bilateral
• More common in Asians, priorbisphosphonate use
• Occur with longer term use >5-10 years
X-rays showing an impending femoral shaft fracture (A) and a representative atypicaldiaphyseal femoral fracture (B) with thickened cortices and a beak or spike. [Courtesy of J.
Lane and A. Unnanuntana, Hospital for Special Surgery, New York, NY.].
Watts N B , Diab D L JCEM 2010;95:1555-1565
©2010 by Endocrine Society
6/11/2015
20
Teriparatide [rDNA origin] injection
FORTEO®
60
Parathyroid hormone (PTH) –Mechanism of action
PTH binds to cell surface G protein-coupled receptor
Decreased apoptosisof osteoblasts
Stimulates differentiationof bone lining cells and
preosteoblasts to osteoblast
Net increase in number and action of bone forming osteoblasts
6/11/2015
21
Teriparatide Indications
• Previous Fragility Fracture inpostmenopausal women and men
• T score: -3.0 without fracture
• Cannot tolerate another therapy
• Bone loss or fracture on another therapy
Teriparatide
• The teriparatide Pen is a prefilled deliverydevice that can be used up to 4 weeks (28daily doses)
• Dose: 20 mcg once daily
• Administered as a subcutaneous injection intothe thigh or abdominal wall
• Duration of therapy: 18-24 months
6/11/2015
22
Side Effects of Teriparatide
• Mild transient increase in serum calcium
• Mean increase in urine calcium of 30 mg in 24 hrs
• Leg cramps
• Dizziness
• Black Box warning-- incidence ofosteosarcoma with high dose longer-termexposure
• Transient tachycardia/HTN after 1st dose
In male and female rats, teriparatide caused an increase in the incidence of
osteosarcoma (a malignant bone tumor), that was dependent on dose and
treatment duration. The effect was observed at systemic exposures to teriparatide
ranging from 3 to 60 times the exposure in humans given a 20 mcg dose. Because of
the uncertain relevance of the rat osteosarcoma finding to humans, teriparatide
should be prescribed only to patients for whom the potential benefits are
considered to outweigh the potential risk. Teriparatide should not be prescribed for
patients who are at increased baseline risk for osteosarcoma (including those with
Paget’s disease of bone or unexplained elevations of alkaline phosphatase, open
epiphyses, or prior external beam or implant radiation therapy involving the
skeleton) (see WARNINGS and PRECAUTIONS, Carcinogenesis)
FORTEO® (teriparatide [rDNA origin] injection)Important Safety Information
Warning
Contraindications to Forteo
• Paget’s disease/ alkaline phosphatase
• History of radiation to bone
• Open Epiphyses
• Primary or Metastatic skeletal malignancy
• Hypercalcemia or increased PTH
• Pregnancy/lactation
• Renal insufficiency
6/11/2015
24
RALOXIFENE
• FDA approved for treatment of osteoporosis inpostmenopausal women
• Reduced risk of new vertebral fractures byabout 55% and 30% in women with priorvertebral fractures
• Did not reduce fracture risk in hip andnonvertebral in clinical trials
• Increased risk of DVT, hot flashes, and CVA inhigh risk populations
Denosumab
• Human monoclonal antibody
• Binds to Rank-L and prevent it from binding toRANK
• Action: inhibits osteoclasts
• Works like OPG
72
Regulation of osteoclastogenesis by factorsfrom osteoblast/stromal cells
Hofbauer LC & Heufelder AE, JMol Med, 2001;79:243-253
Osteoclast precursor
Differentiation
Inhibition
OPG"decoy receptor"
Osteoblast / stromal cell
M - CSF RANK
RANKL
RANKL
Mature osteoclast
6/11/2015
25
Freedom Trial
• Randomized, placebo-controlled trial
• 60 mg of Denosumab SQ every 6 months for 3years
• Reduced vertebral fracture risk by 68%
• Reduced hip fractures by 40%
• Reduced nonvertebral fractures by 20%
Side Effects of Denosumab
• Increased skin infections: cellulitis, erysipelas
• Over-suppression of the bone
• Atrial fibrillation, ONJ, and mortality weresimilar in placebo group and treated group.
New Therapies
• Odanacatib—cathepsin-K inhibitor. Currentlyin phase III clinical trials
• Romosozumab—anti-sclerostin abs. Currentlyin phase III clinical trials
• PTHrp—Phase III clinical trials
6/11/2015
26
Romosozumab
• 12 month phase II trial data showed whengiven every month significant improvementsin BMD—more than other medications
• Bone formation!
NEJM, 2014
Romosozumab
NEJM, 2014
Romosozumab
NEJM, 2014
6/11/2015
27
Sarcopenia and Osteoporosis
• Sarcopenia = age-related loss of muscle mass, strength, and
functionality
• Sarcopenia and osteoporosis go hand-and -hand as muscles
generate the mechanical stress required to keep our bones
healthy
• Increasingly now recognized as a serious health problem thatafflicts millions of aging adults
WILL YOUR BONES LAST AS LONG AS YOU DO?
Any questions orcomments?
6/11/2015
28
Osteonecrosis of the Jaw
• Def: Exposed bone in the maxillofacial regionthat does not heal within 8 weeks in a patientexposed to an anti-resorptive agent (BP orDmab)
• Decreased osteoclast activity plays a role
• Typically devlops after a tooth extraction orother ivasive oral surgical procedure
Osteonecrosis of the Jaw (ONJ)